Please login to the form below
Questcor
This page shows the latest Questcor news and features for those working in and with pharma, biotech and healthcare.
US piles pressure on Mallinckrodt over alleged Acthar fraud
The NDA approval was awarded to Acthar’s earlier owner Questcor, which was acquired by Mallinckrodt for $5.6bn in 2014.
Latest news
-
Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'
Questcor allegedly increased the price to $750 immediately after buying the asset but the big jump was still to come. ... The price continued to tick up over the following years, both before and after Mallinckrodt paid $5.6bn to acquire Questcor in 2014
-
Mallinckrodt pays $1.2bn for Sucampo Pharma
bought Cadence Pharma for $1.3bn, Questcor for $6.5bn, immunotherapy outfit Therakos for $1.3bn and nuclear imaging specialist IBA Molecular for £690m in the last three years.
-
Ireland's Mallinckrodt buys US regenerative medicine firm
Ikaria. . In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for
-
Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase
This includes the $5.6bn deal for Questcor Pharmaceuticals last year and its purchase of Cadence Pharmaceuticals for $1.3bn.
-
Mallinckrodt cuts $5.6bn deal to buy Questcor
Under the terms of the deal, Questcor's shareholders will receive $30 in cash and 0.897 Mallinckrodt shares for each share they own. ... Trudeau will be CEO of the combined company, while three other Questcor executive, including CEO Don Bailey, will
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Deal Watch table for April 2014
7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.
-
Pharma deals during April 2014
wholesale takeovers with deals in Devices (Biomet/ Zimmer Holdings, AccessClosure/ Cardinal Health; New Wave Surgical/ Covidien), Generics/ Speciality Pharma (Questcor/ Mallinckrodt, Ranbaxy Laboratories/ Sun Pharmaceuticals; Silom Medical Company/
-
Deal Watch table for June 2013
165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Questcor appoints SVP corporate strategic development
Michael Aldridge joins from Australian early development company Xenome. US biopharma Questcor Pharmaceuticals has named Michael Aldridge as its first senior VP, corporate strategic development. ... Development programmes that complement Acthar are also
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AstraZeneca blocks take-private buyout of Sobi
- Lilly’s combination antibody expanded to children under 12
- Working with purpose and putting talent development at the heart of operations
- A Lucid Thirsty Thursday D&I Special
- Diversity in clinical trials: looking back at our 2021 blogs
- MHRA approves second COVID-19 antibody treatment
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Novo Nordisk growth takes a hit with China deal
- Innovation in a digital context is not about technology – it’s about people
PMHub
Lucid Group Communications Limited
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
